BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1478 related articles for article (PubMed ID: 16024750)

  • 1. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KEEPS: The Kronos Early Estrogen Prevention Study.
    Harman SM; Brinton EA; Cedars M; Lobo R; Manson JE; Merriam GR; Miller VM; Naftolin F; Santoro N
    Climacteric; 2005 Mar; 8(1):3-12. PubMed ID: 15804727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE
    Ann N Y Acad Sci; 2006 Nov; 1089():444-53. PubMed ID: 17261787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHI risks: any relevance to menopause management?
    Burger HG
    Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F; Taylor HS; Karas R; Brinton E; Newman I; Clarkson TB; Mendelsohn M; Lobo RA; Judelson DR; Nachtigall LE; Heward CB; Hecht H; Jaff MR; Harman SM;
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for hormone therapy: the post-Women's Health Initiative era.
    Reed SD; Newton KM; Lacroix AZ
    Endocrinol Metab Clin North Am; 2004 Dec; 33(4):691-715. PubMed ID: 15501641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S
    Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
    Grodstein F; Manson JE; Stampfer MJ
    J Womens Health (Larchmt); 2006; 15(1):35-44. PubMed ID: 16417416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogens and cerebrovascular stroke: what do animal models teach us?
    Wise PM
    Ann N Y Acad Sci; 2005 Jun; 1052():225-32. PubMed ID: 16024765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.